

Docket No.: 20555/1203301-US3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Daniel G. Chain

Application No.: 10/084,380

Filed: February 28, 2002

Art Unit: 1649

For: **SPECIFIC ANTIBODIES TO AMYLOID  
BETA PEPTIDE, PHARMACEUTICAL  
COMPOSITIONS AND METHODS OF  
USE THEREOF**

Examiner: O. N. Chernyshev

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination under 37 CFR 1.114 (37 CFR 1.97(b)(4)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications.

The documents listed as Cite No. 16-23 in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application number 09/402,820, filed October 12, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.


Dated: January 10, 2006

Respectfully submitted,

By   
Mitchell Bernstein, Ph.D.

Registration No.: 46,550  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	20555/1203301-US3
-------	---	----	---	------------------------	-------------------

**Complete if Known**

Application Number	10/084,380
Filing Date	February 28, 2002
First Named Inventor	Daniel G. Chain
Art Unit	1649
Examiner Name	O. N. Chernyshev

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
1	4,741,901 B1	05-03-1988	Levinson et al.		
2	5,593,846 B1	01-14-1997	Schenk et al.		
3	5,604,102 B1	02-18-1997	McConlogue et al.		
4	5,786,180 B1	07-28-1998	Konig et al.		
5	5,851,996 B1	12-22-1998	Kline		
6	6,287,793 B1	09-11-2001	Schenk et al.		
7	6,610,493 B1	08-26-2003	Citron et al.		
8	6,710,226 B1	03-23-2004	Schenk		
9	6,717,031 B2	04-06-2004	Games et al.		
10	6,743,427 B1	06-01-2004	Schenk		
11	6,761,888 B1	07-13-2004	Schenk		
12	6,787,523 B1	09-07-2004	Schenk		
13	6,905,686 B1	06-14-2005	Schenk		
14	6,913,745 B1	07-05-2005	Schenk		
15	6,923,964 B1	08-02-2005	Schenk		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
16	WO 96/25435 A1		08-22-1996	Konig et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
17		Duenas et al, <i>Bio Techniques</i> , 16(3):476-482 (1994)	
18		Goding, <i>Monoclonal Antibodies</i> , Academic Press Inc., London, pp. 56-97 (1983)	
19		Jarrett et al., "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease," <i>Biochemistry</i> 32:4693-4697 (1993).	
20		Quitschke et al., "The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid $\beta$ -protein precursor promoter," <i>J. Biol. Chem.</i> 271(36), pp. 22231-22239 (1996)	
21		Saido et al., "Autolytic transition of $\mu$ -calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms," <i>J. Biochem.</i> 111:81-86 (1992).	
22		Saido et al., "In situ capture of mu-calpain activation in platelets," <i>J. Biol. Chem.</i> 268(10): (1993) (Abstract Only)	
23		Saido et al., "Spatial resolution of the primary $\beta$ -amyloidogenic process induced in postischemic hippocampus," <i>J. Biol. Chem.</i> 269(21):15253-15257 (1994).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Date Considered
-----------------